Meilleure Health International Industry Group Limited Overview
Meilleure Health is a controlled, micro-cap Hong Kong holding company whose public identity is "health" but whose economic substance is overwhelmingly property and lending. Reported revenue in FY2025 was only HK$36.5m, of which rental income from PRC investment properties contributed more than half, while interest earned on a HK$491m loan book (HK$29.3m) was nearly as large as total gross profit [AR25]. Its healthcare activities — functional-medicine clinics in Shenzhen and Nanjing, the Jixiaojian medical-aesthetics-plus-skincare brand, the Swiss CBD brand AlpReleaf and minority stakes in cell-therapy developers Wingor Bio and Mei Ai Kang — generated HK$16.1m of revenue and a segment loss. A 109-unit townhouse project in Alphington, Melbourne began handing over units in H1 2026, lifting interim revenue nine-fold to HK$164.6m [IR26]. The shares trade at roughly 0.65x book, with the Zhou family controlling around 56–60% of the equity.
The company's own description
[AR25] defines the Group's principal activities as healthcare-related business, trading of construction materials and renewable energy products, real estate agency services, property investment and leasing, development of residential properties, and procurement services for renewable energy products. Management frames its long-run ambition around China's "Healthy China 2030" policy, with skin health management as the strategic anchor, cell therapy and health management as synergistic innovation areas, and a stated aspiration to move from selling health products to exporting health concepts. The corporate vision repeated in both [AR25] and [IR26] is "using technology and expertise to serve more people's health and beauty needs."
Independent characterisation
On the evidence of the financial statements, Meilleure Health is best characterised as a family-controlled investment holding company with four economic engines of very different weight:
-
PRC investment property landlord — HK$678.3m of investment properties at fair value (30 Jun 2026), all situated in the PRC and held on medium-term leases, generating HK$19.2m of rent in FY2025 (≈2.9% gross yield on the year-end fair value of HK$663.4m) [AR25], [IR26]. HK$509.1m of these properties are pledged to banks [IR26].
-
Lender — a HK$441.2m loan book at 30 Jun 2026 (HK$491.2m at end-2025), more than half of which (HK$230.7m, 52.3%) is owed by U-light Energy (Guangyu Zhaoneng New Energy Group), a related party in which the Group holds 3.168%, at one-year LPR + 3.05% and guaranteed personally by the controlling shareholder; the remainder is unsecured short-term loans to eight independent borrowers at 3–8% [IR26]. Interest income (HK$29.3m in FY2025) exceeded rental income [AR25].
-
Residential developer (Australia) — a wholly-owned 109-townhouse project on an 11,488 sq.m. site at 626 Heidelberg Road, Alphington, VIC (6.5 km from Melbourne CBD; GFA ≈18,752 sq.m.), marketed as "Yarrabend", built with Level 10 Pty Ltd and designed by Rothelowman; pre-sales started November 2022 and first-phase handovers began in H1 2026, producing HK$151.9m of property-sale revenue at a low (≈13%) gross margin [AR25], [IR26].
-
Healthcare and consumer health — clinics, aesthetics services, skincare and CBD products (HK$16.1m revenue in FY2025; HK$4.4m in H1 2026), plus equity-accounted and FVTPL stakes in cell-therapy companies held within the "equity investment" segment [AR25], [IR26].
A residual trading business (construction materials, renewable-energy products and procurement services) has shrunk from HK$149m of revenue in FY2021 to HK$1.2m in FY2025 and HK$0.1m in H1 2026 [SA], [AR25], [IR26].
Revenue model mix
| Revenue model (FY2025, HKD Mn) | Amount | Share of revenue |
|---|---|---|
| Lease/rental (recurring) — investment properties | 19.2 | 52.6% |
| Product sales — healthcare-related products | 9.4 | 25.8% |
| Services — aesthetic medical | 5.4 | 14.9% |
| Services — healthcare management | 1.3 | 3.6% |
| Agency/commission — healthcare product sale agency | 0.8 | 2.2% |
| Services — renewable energy procurement | 0.4 | 1.0% |
| Total revenue | 36.5 | 100.0% |
Source: [AR25] Note 4. Note that interest income (HK$29.3m) and fair-value gains on investment properties (HK$21.7m) are recorded outside revenue but are central to the profit model.
In H1 2026 the mix inverted: sale of completed properties (HK$151.9m) was 92.3% of revenue, rental 5.0%, healthcare 2.6% [IR26].
Value chain position, customers, end-markets
Property: owner-landlord of PRC commercial units (several acquired from vehicles connected to the controlling shareholder, e.g., Yuye Tianyi Commercial Plaza units in Kunshan); developer-seller to retail homebuyers in Melbourne.
Lending: provider of short-term working-capital loans to corporates and individuals sourced through management's networks [AR25].
Healthcare: downstream consumer-facing services (clinics, aesthetics) and branded consumer products sold through clinics, a medical-aesthetics chain partner (BeauCare Clinics), livestreamers on Taobao, Douyin and Xiaohongshu, and European distribution for AlpReleaf (22 countries) [AR25].
Customers: consumers (aesthetics, health management, CBD), PRC tenants (commercial leasing), Australian homebuyers, corporate borrowers; geographically 96% PRC in FY2025 revenue, shifting to Australia in 2026 [AR25], [IR26].
Strategy
Stated strategy themes (paraphrased from [AR25] and [IR26])
Skin health management as strategic anchor: keep refining the Jixiaojian products and model combining efficacy skincare with medical aesthetics; integrate online and offline channels; build a "scientific skincare brand".
Cell therapy and health management synergy: deepen R&D and application presence via Wingor Bio and Mei Ai Kang and explore commercialisation pathways that link to the clinics.
- Dual engines of technology R&D and brand value, aiming to transform the group from a provider of products into a provider of health concepts.
Overseas expansion: strengthen AlpReleaf channels in Europe and complete the Australian townhouse project.
Opportunistic diversification: explore businesses with stable cash flows or high growth potential (the Jiangsu Yide rental acquisition is the clearest recent example).
Shareholder returns: dividends and buybacks explicitly cited as ongoing tools [IR26].
Initiatives in the last 24 months
| Date | Initiative | Detail / target |
|---|---|---|
| 31 Jan 2024 onward | U-light Energy revolving facility | Up to RMB200m at LPR+3.05%, drawdown period to 31 Dec 2026; HK$230.7m outstanding at 30 Jun 2026 |
| Nov 2024 | Kunshan commercial units acquisition | RMB13.4m, rental property |
| Jan 2025 | Accelerated Australian sell-down incl. sale to CEO | AUD1.36m unit; expected gain ≈AUD249k [DT25 press coverage] |
| 2,025 | Share repurchases | 29.706m shares, HK$8.85m [AR25] |
| Aug 2025 | Introduction of interim dividend | HK0.15 cents, repeated in Aug 2026 |
| Jan 2026 | Buyback programme | Up to 10% of shares under June 2025 mandate |
| Jan 2026 | Jiangsu Yide acquisition | RMB124.767m; ≈RMB7.8m annual rent (≈5.97% yield) |
| Apr 2026 | 2026 Share Award Scheme | Employee/director incentive |
| H1 2026 | Alphington handovers | First phase delivered; HK$151.9m revenue |
ESG/sustainability commitments: none quantified in the announcements reviewed. Cost programmes: none announced; operating expenses broadly flat at ≈HK$31m (FY2024–FY2025). Medium-term financial targets / guidance: not provided; the company issues only profit alerts as required by the Listing Rules.
Products & Services
Pricing models are not publicly disclosed for any product line unless noted.
Healthcare-related segment
| Offering | Description & capabilities | Target customer | Launch / status | Disclosed flagship elements |
|---|---|---|---|---|
| Shenzhen high-end health management clinic | International-standard health management grounded in functional medicine; operated by an experienced professional team | Affluent urban PRC consumers | Shenzhen anti-ageing/health management advisory centre planned for H2 2017; operating "steadily" per [IR26] | Client-retention emphasis; management-system optimisation |
| Nanjing high-end health management clinic | As above | Affluent consumers in Jiangsu | Operating per [AR25], [IR26] | — |
| Healthcare management services (revenue line) | Over-time service revenue | Clinic members | FY2025 revenue HK$1.3m (FY2024: HK$4.5m); H1 2026 HK$1.16m | — |
| Jixiaojian (肌小簡) brand | Curated brand combining light medical aesthetics and efficacy skincare; regimen positioned as 60% non-invasive aesthetic treatment + 40% simplified skincare | Younger PRC consumers seeking light medical aesthetics | Launched H2 2021 | Photoelectric repair series; medical-grade dressing series; exosome-based premium anti-ageing series |
| Jixiaojian medical aesthetics clinic | Signature "Jixiaojian × Super Photon" protocol covering pre-, intra- and post-treatment care | Aesthetics clients | Operating "for years" [AR25] | Clinical demonstration base for Lumenis; Peninsula Medical (半島) soothing device project |
| Aesthetic medical services (revenue line) | Point-in-time service revenue | — | FY2025 HK$5.4m (FY2024 HK$7.6m); H1 2026 HK$1.5m | — |
| Healthcare-related products (revenue line) | Skincare and health products | Consumers via clinics, BeauCare Clinics, livestream channels | FY2025 HK$9.4m (FY2024 HK$7.5m); H1 2026 HK$1.4m | Raw materials from DSM and Ashland; supramolecular lab with Shinehigh Innovation; recombinant collagen partnership with Jland Biotech |
| AlpReleaf | Premium CBD health and wellness brand developed and produced in Switzerland; lines for relaxation, sleep support and muscle soreness relief | European consumers | Launched 2021; EU and UK certification; access to 22 European countries | — |
| CBD downstream products (revenue line) | — | — | FY2025 nil (FY2024 HK$9k); H1 2026 HK$0.26m | — |
Trading segment
| Offering | Description | Status / revenue |
|---|---|---|
| Construction materials trading | Bulk construction materials sold in the PRC | HK$10.5m in FY2024; nil in FY2025 [AR25] |
| Renewable energy products sale | Sale of renewable energy products | HK$1.05m FY2024; nil FY2025; HK$0.1m H1 2026 |
| Renewable energy procurement services | Procurement on behalf of customers; prepayments and performance bonds placed with suppliers to secure pricing for 2–3 years | HK$0.36m FY2025 (FY2024 HK$1.0m); prepayments to suppliers HK$45.3m at 30 Jun 2026 |
| Healthcare product sale agency | Commission-based agency | HK$0.8m FY2025; nil H1 2026 |
Property-related segment
| Asset / service | Description | Key data |
|---|---|---|
| PRC investment property portfolio | Commercial properties in the PRC held for rental, valued by income (term and reversion) and direct comparison approaches | Fair value HK$663.4m (end-2025), HK$678.3m (30 Jun 2026); rental income HK$19.2m FY2025, HK$8.2m H1 2026 |
| Kunshan units (Yuye Tianyi Commercial Plaza) | Units 7 and 12, 1/F, Tower 13, 65 Jintang Road, Zhoushi Town, Kunshan; 514.54 sq.m. | Acquired for RMB13.4m (agreement 29 Nov 2024) [MS] |
| Alphington / "Yarrabend" townhouses | 109 townhouses, site 11,488 sq.m., GFA ≈18,752 sq.m., Lot A & B 626 Heidelberg Road, Alphington VIC 3078 | Carrying value HK$310.6m at 30 Jun 2026; H1 2026 sales HK$151.9m; construction commitments HK$61.5m [IR26] |
| Real estate agency services | Listed as a principal activity | Revenue not separately disclosed in FY2025 |
| Jiangsu Yide (pending/proposed) | PRC equity-investment and property-leasing company; properties mostly leased; annual rent ≈RMB7.8m (≈5.97% yield on consideration) | Consideration RMB124.767m; approved at SGM 21 Apr 2026 [JY26], [SGM26] |
Equity investment segment (principal holdings disclosed)
| Holding | Nature | Disclosed facts |
|---|---|---|
| Shenzhen Wingor Biotechnology (Wingor Bio, 深圳市茵冠生物科技) | Cell therapy (stem cells, immune cells, exosomes, "genetic engineering +"); National High-Tech Enterprise | Stake acquired 2019, partly sold 2021 (consideration receivable by 2028); 7 cell-drug IND applications accepted by NMPA; 3 approved into clinical trials, incl. WG103 (umbilical-cord MSC for acute ischaemic stroke, Phase II from Jul 2025) and an MSC injection for premature ovarian insufficiency (Jan 2026) [AR25], [IR26] |
| Beijing Mei Ai Kang Technology (北京美艾康) | Cellular immunotherapy | Established 2020; clinical studies with PLA General Hospital Fifth Medical Centre and others; 132 clinical experiments completed; self-transfusion injector patent approved [AR25] |
| U-light Energy (Guangyu Zhaoneng New Energy Group) | Renewable energy; related party | 3.168% held via Wuhu Ruima at 30 Jun 2026 (3.636% at end-2025) [IR26], [AR25] |
| Joint venture (unnamed in announcements) | Equity-accounted | Carrying value HK$31.3m at 30 Jun 2026 (HK$46.4m end-2025); partial disposals generated gains in FY2025 and H1 2026 |
| Associates | Equity-accounted | HK$3.7m at 30 Jun 2026; HK$11.0m capital contribution commitment |
| Total investment portfolio | — | HK$80.4m at 30 Jun 2026 (HK$95.2m end-2025); no single holding >5% of total assets [IR26] |
Treasury/lending "product"
Short-term interest-bearing loans and a long-term revolving facility are offered to identified corporate and individual borrowers to raise returns on cash [AR25]. Terms at 30 Jun 2026: 3–8% fixed for independent borrowers; LPR+3.05% for U-light Energy [IR26].
Financial Narrative
Methodology: FY2024–FY2025 income statement items from [AR25]; FY2021–FY2023 from [SA] (S&P standardised; FY2022 revenue and gross profit match [AR22]). Operating income and EBITDA are S&P-standardised (gross profit less selling, admin and other operating expenses) for all years because the company does not report an operating-profit line. Note: [SA] shows FY2024 gross profit of HK$27.95m vs company-reported HK$28.905m; company figure used.
Income statement
EPS for FY2024–FY2025 as reported [AR25]; FY2021–FY2023 derived from [SA] net income and weighted shares (4,257m; 4,109m; 4,093m basic). DPS: FY2025 = HK0.15 cents interim + HK0.4 cents final [AR25]; FY2022 HK1.6 cents implied by HK$65.5m paid in 2023 [SA]; FY2021 no dividend per [SA].
Margins and growth (%)
Revenue CAGR FY2021–FY2025: −38.4% per annum (HK$253.0m to HK$36.5m). Net income CAGR FY2021–FY2025: −10.9% per annum.
Commentary. The five-year record is one of steep revenue contraction masked by resilient bottom-line profit. Revenue collapsed by 86% over four years as the low-margin trading business (59% of FY2021 revenue) was run down and healthcare demand weakened under what management repeatedly calls "adverse market conditions" in the PRC [AR25]. Gross margin rose mechanically from 40% to 62% because the residual mix is dominated by rental income. From FY2024, operating expenses (≈HK$31m a year of selling and admin costs) exceeded gross profit, producing S&P-basis operating losses. Profit has nonetheless held at HK$32–41m in three of the last four years because of three non-operating pillars: interest income on the loan book (HK$29.3m in FY2025), annual fair-value uplifts on PRC investment property (HK$13.6–23.8m every year), and FX gains (HK$8.4m in FY2025). FY2025's net margin above 100% further reflects an HK$7.5m tax credit, including HK$5.3m of prior-year PRC over-provision [AR25]. The quality of earnings is therefore low: in FY2025 roughly HK$59m of the HK$30.5m pre-tax profit came from interest, revaluation and FX, offset by core operating losses, impairments and finance costs.
The H1 2026 inflection changes the revenue profile but not the margin structure: revenue of HK$164.6m (vs HK$17.5m), gross margin of 17.3% (vs 81.1%), and a property sales gross profit of about HK$20.3m on HK$151.9m of sales (≈13% margin) [IR26]. TTM revenue to June 2026 was HK$183.6m and TTM net income HK$51.2m [SA].
Balance sheet
Sources: FY2024–FY2025 [AR25]; FY2021–FY2023 [SA]. At 30 Jun 2026: total assets HK$1,786.1m; cash HK$7.8m; bank borrowings HK$291.0m (HK$193.2m current, HK$97.7m non-current); total equity HK$1,303.0m; investment properties HK$678.3m [IR26].
Company-defined gearing: net debt (borrowings plus trade payables, contract liabilities, accruals, related-party balances, dividend payable, less cash and restricted deposits) / (equity + net debt) = 26.4% at end-2025 (21.6% end-2024) and 21.3% at 30 Jun 2026; company-defined net debt HK$447.1m (end-2025) and HK$352.4m (30 Jun 2026) [AR25], [IR26].
Commentary. The balance sheet is asset-rich but liquidity-thin. Equity drifted down 13% from HK$1,431m (FY2021) to HK$1,201m (FY2024) — buybacks, dividends and RMB/AUD translation losses outweighed profits — then recovered on FX gains in FY2025 and H1 2026. Cash fell from HK$273m to HK$8m over 4.5 years as cash was redeployed into (a) the loan book (HK$491m at end-2025), (b) Australian development spend (properties under development rose from HK$255m to HK$373m during FY2025), and (c) PRC property acquisitions. Debt rose from HK$170m to HK$381m before falling to HK$291m on Australian settlement proceeds in H1 2026. The group had no unutilised banking facilities at end-2025 or 30 Jun 2026, and HK$637.1m of assets were pledged [AR25], [IR26]. The current ratio looks comfortable only because the loan book and properties under development sit in current assets; the quick ratio is about 0.11 [SA].
Cash flow
Sources: [SA]; FY2025 operating, investing and financing cash flows match [AR25]. H1 2026: operating cash inflow HK$16.1m, investing inflow HK$87.0m (incl. HK$68.5m loan repayments), financing outflow HK$108.7m (incl. HK$146.1m debt repayment) [IR26].
Commentary. Operating cash flow is volatile and driven by working-capital swings in loan receivables (classified partly in operating activities by S&P), Australian construction spend and receivables. FY2024's HK$186m inflow reflected collection of receivables; FY2025's HK$50m outflow reflected HK$92.6m of capitalised development expenditure [AR25]. Across FY2021–FY2025, cumulative FCF was approximately −HK$50m while cumulative shareholder distributions (dividends plus buybacks) were about HK$191m and net borrowing about HK$238m — i.e., distributions have effectively been debt-funded or funded by drawing down the large FY2021 cash pile.
Ratios
Computed from 6.1 and 6.3. Net debt/EBITDA: net cash in FY2021; 1.2x in FY2022; 5.2x in FY2023; not meaningful in FY2024–FY2025 because S&P-basis EBITDA was negative. Cash conversion cycle: not meaningful for this business mix (inventories are almost entirely development property, and revenue is dominated by rent); not calculated.
Commentary. Returns on capital are structurally low — ROE has not exceeded 4.2% in five years, and the only reason it is positive is revaluation, interest and FX income. A business with HK$1.25bn of equity generating HK$30–40m of profit trades, logically, at a deep discount to book (0.65x currently). Coverage looks acceptable only when non-operating income is included; on an operating basis, the company has not covered its interest bill since FY2023.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Products / services |
|---|---|---|
Healthcare-related business | Health management services, aesthetic medical services, sale of healthcare-related and CBD downstream products | Shenzhen and Nanjing functional-medicine clinics; Jixiaojian clinic and skincare; AlpReleaf CBD (Switzerland/Europe) |
Trading business | Trading of construction materials and renewable energy products; procurement services for renewable energy products; healthcare-related product sale agency services | Construction materials (nil in FY2025); renewable energy products; procurement services; agency commissions |
Property-related business | Real estate agency services, leasing of investment properties, development and sale of residential properties | PRC investment property portfolio; Alphington (Melbourne) townhouses |
Equity investment business | Management of investment portfolio | Wingor Bio and other FVTPL holdings, joint venture and associates, FVTOCI equities, derivatives |
Segment revenue (HKD Mn)
| Segment revenue (HKD Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Healthcare-related (incl. industrial hemp) | 52.70 | 53.78 | 48.15 | 19.61 | 16.15 |
Trading | 149.06 | 37.13 | 62.57 | 13.82 | 1.17 |
Property-related | 51.28 | 28.98 | 18.59 | 17.24 | 19.20 |
Equity investment | 0 | 0 | 0 | 0 | 0 |
Total revenue | 253.03 | 119.89 | 129.30 | 50.68 | 36.52 |
Segment share of revenue (%)
| Segment share of revenue (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Healthcare-related | 20.8 | 44.9 | 37.2 | 38.7 | 44.2 |
Trading | 58.9 | 31.0 | 48.4 | 27.3 | 3.2 |
Property-related | 20.3 | 24.2 | 14.4 | 34.0 | 52.6 |
Segment revenue YoY growth (%)
| Segment revenue YoY growth (%) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Healthcare-related | 2.0 | -10.5 | -59.3 | -17.7 |
Trading | -75.1 | 68.5 | -77.9 | -91.5 |
Property-related | -43.5 | -35.9 | -7.3 | 11.4 |
Revenue by Segment and Segment Assets & Liabilities
| Segment result (HKD Mn) | FY2024 | FY2025 |
|---|---|---|
Healthcare-related | -19.31 | -4.15 |
Trading | 7.18 | -4.37 |
Property-related | 39.58 | 31.88 |
Equity investment | 15.61 | -9.72 |
Total segment result | 43.05 | 13.65 |
Segment assets (HKD Mn)
| Segment assets (HKD Mn) | FY2024 | FY2025 |
|---|---|---|
Healthcare-related | 13.13 | 23.59 |
Trading | 90.50 | 48.35 |
Property-related | 929.54 | 1,085.91 |
Equity investment | 116.42 | 106.94 |
Unallocated corporate (incl. loan book) | 487.59 | 519.58 |
Deferred tax assets | 31.46 | 31.22 |
Consolidated total assets | 1,668.65 | 1,815.59 |
Segment Revenue
| Segment (six months) | H1 2025 revenue | H1 2026 revenue | H1 2025 result | H1 2026 result |
|---|---|---|---|---|
Healthcare-related | 6.60 | 4.35 | 0.07 | -0.14 |
Trading | 0.81 | 0.10 | -1.02 | 0.79 |
Property-related | 10.04 | 160.13 | 6.06 | 20.76 |
Equity investment | 0 | 0 | -0.84 | -2.62 |
Total | 17.45 | 164.57 | 4.26 | 18.79 |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (HKD Mn) | 253.03 | 119.89 | 129.30 | 50.68 | 36.52 |
Gross profit (HKD Mn) | 100.93 | 66.76 | 77.21 | 28.91 | 22.63 |
Operating income, S&P basis (HKD Mn) | 57.35 | 30.83 | 35.38 | -3.85 | -9.71 |
EBITDA, S&P basis (HKD Mn) | 58.39 | 32.26 | 36.93 | -2.67 | -8.97 |
Interest and investment income (HKD Mn) | 13.54 | 27.21 | 19.87 | 22.50 | 29.30 |
Fair value gains on investment properties (HKD Mn) | 15.18 | 13.58 | 18.54 | 23.81 | 21.73 |
Finance costs (HKD Mn) | 8.39 | 11.45 | 11.41 | 10.29 | 9.29 |
Profit before tax (HKD Mn) | 85.70 | 25.39 | 52.98 | 45.40 | 30.54 |
Income tax expense (HKD Mn) | 25.25 | 7.61 | 14.49 | 13.36 | -7.46 |
Net income attributable to owners (HKD Mn) | 60.32 | 17.82 | 40.83 | 32.48 | 37.98 |
EPS basic (HK cents) | 1.42 | 0.43 | 1.00 | 0.79 | 0.93 |
EPS diluted (HK cents) | 1.41 | 0.43 | 1.00 | 0.79 | 0.93 |
Dividend per share declared (HK cents) | 0 | 1.6 | 0.4 | 0.4 | 0.55 |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin (%) | 39.9 | 55.7 | 59.7 | 57.0 | 62.0 |
Operating margin, S&P basis (%) | 22.7 | 25.7 | 27.4 | -7.6 | -26.6 |
EBITDA margin (%) | 23.1 | 26.9 | 28.6 | -5.3 | -24.6 |
Pre-tax margin (%) | 33.9 | 21.2 | 41.0 | 89.6 | 83.6 |
Net margin (%) | 23.8 | 14.9 | 31.6 | 64.1 | 104.0 |
Revenue growth YoY (%) | -4.6 | -52.6 | 7.8 | -60.8 | -27.9 |
Balance Sheet
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (HKD Mn) | 1,737 | 1,711 | 1,697 | 1,669 | 1,816 |
Cash and equivalents (HKD Mn) | 272.59 | 210.99 | 106.31 | 29.94 | 13.08 |
Cash plus short-term investments (HKD Mn) | 380.39 | 210.99 | 106.31 | 29.94 | 13.08 |
Short-term bank borrowings (HKD Mn) | 58.34 | 78.24 | 159.30 | 83.18 | 271.32 |
Long-term bank borrowings (HKD Mn) | 110.36 | 165.20 | 137.32 | 218.65 | 109.08 |
Total debt incl. leases (HKD Mn) | 170.42 | 249.13 | 297.06 | 303.06 | 380.96 |
Net debt, debt minus cash and ST investments (HKD Mn) | -209.97 | 38.14 | 190.75 | 273.12 | 367.88 |
Total equity (HKD Mn) | 1,431 | 1,327 | 1,254 | 1,201 | 1,248 |
Goodwill and intangibles (HKD Mn) | 18.57 | 18.54 | 18.50 | 0 | 0 |
Investment properties (HKD Mn) | 0 | 0 | 0 | 610.29 | 663.39 |
Working capital (HKD Mn) | 764.81 | 785.08 | 694.79 | 529.95 | 654.25 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (HKD Mn) | -83.27 | 43.15 | -136.49 | 186.00 | -50.02 |
Capital expenditure (HKD Mn) | -6.48 | -1.01 | -0.83 | -0.13 | -0.58 |
Free cash flow (HKD Mn) | -89.75 | 42.14 | -137.32 | 185.86 | -50.60 |
Investing cash flow (HKD Mn) | 161.56 | -134.76 | 53.72 | -253.98 | 14.64 |
Financing cash flow (HKD Mn) | -38.22 | 41.93 | -18.90 | -6.39 | 18.07 |
Dividends paid (HKD Mn) | 0 | 0 | 65.50 | 16.38 | 22.52 |
Share buybacks (HKD Mn) | 40.68 | 37.02 | 0.34 | 0 | 8.86 |
Net new borrowing (HKD Mn) | 10.74 | 90.06 | 58.17 | 20.25 | 58.70 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE, on year-end equity (%) | 4.2 | 1.3 | 3.3 | 2.7 | 3.0 |
ROA, on year-end assets (%) | 3.5 | 1.0 | 2.4 | 1.9 | 2.1 |
Pre-tax ROIC, EBIT / (equity + debt) (%) | 3.6 | 2.0 | 2.3 | -0.3 | -0.6 |
Current ratio (x) | 7.90 | 6.73 | 4.10 | 4.35 | 2.81 |
Debt to equity (x) | 0.12 | 0.19 | 0.24 | 0.25 | 0.31 |
Interest coverage, EBIT / finance costs (x) | 6.84 | 2.69 | 3.10 | -0.37 | -1.05 |
Interest coverage, (PBT + finance costs) / finance costs (x) | 11.2 | 3.2 | 5.6 | 5.4 | 4.3 |
Asset turnover, revenue / total assets (x) | 0.146 | 0.070 | 0.076 | 0.030 | 0.020 |
Region revenue (HKD Mn)
| Region revenue (HKD Mn) | FY2024 | FY2025 |
|---|---|---|
PRC | 46.52 | 35.10 |
Hong Kong | 0 | 0.22 |
Europe | 2.87 | 1.20 |
Others | 1.29 | 0 |
Total | 50.68 | 36.52 |
Region growth YoY (%)
| Region growth YoY (%) | FY2025 |
|---|---|
PRC | -24.5 |
Europe | -58.3 |
Six Months to 30 Jun 2026 Details
| Six months to 30 Jun 2026 (HKD Mn) | Healthcare | Property | Trading | Total |
|---|---|---|---|---|
PRC | 4.09 | 0 | 0 | 4.09 |
Australia | 0 | 151.94 | 0 | 151.94 |
Others | 0.26 | 0 | 0.10 | 0.36 |
Total (excl. rental income HK$8.18m, PRC) | 4.35 | 151.94 | 0.10 | 156.39 |
Six months to 30 Jun 2025 (HKD Mn) | Healthcare | Trading | Total | — |
PRC | 6.42 | 0 | 6.42 | — |
Others | 0.18 | 0.81 | 0.99 | — |
Total (excl. rental income HK$10.04m, PRC) | 6.60 | 0.81 | 7.41 | — |
Non-current assets by location (HKD Mn)
| Non-current assets by location (HKD Mn) | FY2024 | FY2025 |
|---|---|---|
PRC | 668.98 | 717.07 |
Hong Kong | 0.01 | 0.01 |
Europe | 0.02 | 0.01 |
Valuation Snapshot
| Metric | Value | Source |
|---|---|---|
Last price | HK$0.208 (9 Oct 2026) | [SA] |
52-week change | −27.0% | [SA] |
50-day / 200-day moving average | HK$0.23 / HK$0.26 | [SA] |
Beta (5-year) | 0.12 | [SA] |
Average daily volume (20 days) | ≈225,600 shares | [SA] |
Approx. 3-year change (vs implied end-2023 ≈HK$0.246) | ≈−15% (implied; approximate) | Derived from [SA] P/S and revenue |
Approx. 5-year change (vs implied end-2021 ≈HK$0.48) | ≈−57% (implied; approximate) | Derived from [SA] P/S and revenue |
Implied year-end share price (HKD) | FY2021 | FY2022 |
Implied price (HK$, from aggregator P/S x revenue / shares) | 0.48 | 0.29 |
Valuation Multiples
| Multiple | Meilleure Health | Peer comparison |
|---|---|---|
P/E (TTM) | 16.6x | Peer multiples not compiled/verified |
P/B | 0.65x | — |
EV/Sales (TTM) | 6.1x | — |
EV/EBITDA | Not meaningful (TTM EBITDA ≈HK$1.5m) | — |
Earnings yield | 6.1% | — |
Dividend yield (trailing) | 2.64% | — |
Dividend per share (HK cents)
| Dividend per share (HK cents) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Interim | 0 | 0 | 0 | 0 | 0.15 |
Final | 0 | 1.6 | 0.4 | 0.4 | 0.4 |
Total | 0 | 1.6 | 0.4 | 0.4 | 0.55 |
Dividends & Capital Returns
| Buyback activity | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Buyback cash outflow (HKD Mn) | 40.68 | 37.02 | 0.34 | 0 | 8.86 |
Capital Markets Data
| Bank borrowings maturity (HKD Mn) | 31 Dec 2024 | 31 Dec 2025 | 30 Jun 2026 |
|---|---|---|---|
Within 1 year | 83.18 | 271.32 | 193.23 |
1–2 years | 120.97 | 33.43 | 35.08 |
2–5 years | 66.98 | 51.28 | 42.07 |
Over 5 years | 30.69 | 24.37 | 20.59 |
Total | 301.82 | 380.40 | 290.97 |
Analyst Conclusions
Management guidance
No quantitative guidance. Management expresses confidence, cites net current assets of HK$702.0m at 30 Jun 2026, and commits to skin-health focus, prudent exploration of new growth avenues, overseas expansion and continued capital returns [IR26]. Consensus growth expectations: not available (no coverage).
Bull case
-
Deep discount to tangible book with a monetisation catalyst: shares trade at ≈0.65x book; the remaining HK$310.6m of Alphington inventory and HK$441m of short-dated loans could convert to cash, reduce debt and support larger distributions.
-
Rising recurring income base: rental income plus the Jiangsu Yide addition (≈RMB7.8m a year) and LPR-linked interest could lift recurring pre-tax income even without healthcare improvement.
-
Free option on cell therapy: Wingor Bio's seven INDs and Phase II stroke programme, in a policy environment that formalised cell-therapy regulation in 2025, could crystallise value well above the HK$80m portfolio carrying value.
Bear case
-
Related-party credit risk: HK$230.7m owed by U-light Energy (≈18% of equity), unsecured by assets and due by 31 Dec 2026, guaranteed only by the controlling shareholder.
-
Low-quality, non-recurring earnings: core operations lose money; profits depend on revaluation, interest, FX and tax credits, all of which can reverse.
-
Governance discount is structural: repeated connected acquisitions and a controlling family stake of ≈56–60% mean discount-to-NAV may persist; liquidity is thin (≈34% float, low volumes).
Catalysts and monitorables (next 12 months)
| Monitorable | Why it matters | Timing |
|---|---|---|
| Repayment/renewal of U-light Energy facility | Largest single credit exposure; drawdown period ends | By 31 Dec 2026 |
| Completion of Jiangsu Yide acquisition | Cash outflow ≈HK$137m; rental uplift | Pending (deposits paid HK$75.2m at 30 Jun 2026; link unconfirmed) |
| Further Alphington settlements | Revenue, cash, deleveraging | H2 2026 – 2027 |
| FY2026 PRC investment-property valuation | Major profit swing factor | FY2026 results (≈Mar 2027) |
| Refinancing of HK$193m current borrowings | Liquidity | Rolling |
| Wingor Bio clinical readouts / financing | Equity-investment valuation | Ongoing |
| Healthcare segment trajectory | Strategic credibility | FY2026 results |
| Buyback execution under 10% mandate | Signal of NAV discount closure | Ongoing |
Analyst verdict
Meilleure Health is a health company in name and narrative, but a property-and-credit vehicle in substance. Of HK$1.8bn in assets, roughly HK$680m is PRC investment property, HK$440–490m is a loan book half-owed by a related renewable-energy company, and HK$310m is Melbourne townhouse inventory; the healthcare operations that give the group its name hold about 1% of assets and lost money in FY2025. Revenue has fallen at a 38% compound rate over four years, and S&P-basis operating income has been negative since FY2024. That the company still reported HK$38m of profit in FY2025 and HK$28m in H1 2026 is a tribute to interest income, revaluation gains, FX translation and Australian settlements — real economic flows, but not the recurring, scalable franchise a health investor would want.
The valuation already reflects much of this. At HK$0.208, the market capitalisation of ≈HK$844m sits at 0.65x book, and the trailing dividend yield is ≈2.6% with ongoing buybacks. The H1 2026 interim shows the balance sheet turning: debt cut by HK$89m, net current assets up to HK$702m. If Alphington settlements continue and the U-light Energy facility is repaid on time at the end of 2026, the discount to NAV could narrow and distributions could rise.
The decisive variables are governance and credit rather than healthcare. The repeated pattern of related-party transactions — property purchases from the controlling shareholder's group, a large loan to a related company, a pending RMB125m acquisition from a Zhou-controlled vendor — means minority investors are exposed to decisions in which their interests and the controller's may diverge. Absent sell-side coverage, institutional ownership and quantified guidance, information asymmetry is high.
Verdict: a deep-value, special-situation NAV stock rather than a growth or healthcare play.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure (approx.) | Background (public sources) | Age |
|---|---|---|---|---|
Mr. Zhou Xuzhou (周旭洲) | Executive Director, Co-Chairman; ultimate controlling shareholder | Chairman since Aug 2013 | Founder of U-Home Group (宇業集團), Chuzhou Yuda Property Development and Huangshan Yulong Industry; director of U-Home Group International and Wuhu Meilleure; Wuhan University graduate (1985) [MS] | — |
Dr. Zeng Wentao (曾文濤) | Executive Director, Co-Chairman | Since 20 Jun 2019 | Founder of Hainan Sanyou Real Estate (1990) and Wuhan Yinhai Properties (1995); CEO of Zhongjia Capital (Wuhan) Investment Management since 2017; former Vice Chairman, Hubei Federation of Industry & Commerce; doctorate from Wuhan University [MS] | Born 1963 [WEBB] |
Ms. Zhou Wen Chuan (周文川) | Executive Director, Vice-Chairman and CEO | CEO since 23 Sep 2013 | University of British Columbia (bachelor's 2007, master's 2008); CUHK MBA (2011); director of Gongniu Group and Wingor Bio [MS]; described in company filings as an associate of Mr. Zhou Xuzhou [CT23] | ≈41–42 [SWS] |
Dr. Mao Zhenhua (毛振華) | Non-executive Director | — | Economist; founder and chairman of China Chengxin (credit rating) group; Wuhan University professor; multiple listed-company directorships [MS] | Born Jan 1964 [WEBB] |
Prof. Chau Chi Wai, Wilton (周志偉) | Independent Non-executive Director | — | — | — |
Mr. Chen Shi | Independent Non-executive Director | Appointed between Apr 2023 and Apr 2024 (replaced Dr. Yang Yu) | — | — |
Mr. Wu Peng (吳鵬) | Independent Non-executive Director | — | — | Born 1982 [WEBB] |
“—” = not publicly disclosed.
Directors' Remuneration
| Director | Audit | Remuneration | Nomination | Strategic |
|---|---|---|---|---|
Zhou Xuzhou | — | — | Chair | Member |
Zeng Wentao | — | Member | — | Member |
Mao Zhenhua | Member | — | — | Chair |
Chau Chi Wai, Wilton | Chair | Member | Member | — |
Chen Shi | Member | Chair | — | — |
Wu Peng | — | — | Member | — |
Directors' Remuneration — Zhou Xuzhou
| Director | Fees | Salary & benefits | Retirement | Share-based | Total |
|---|---|---|---|---|---|
Zhou Xuzhou | 0 | 800 | 0 | 0 | 800 |
Zhou Wen Chuan | 0 | 1,200 | 18 | -557 | 661 |
Zeng Wentao | 0 | 0 | 0 | -299 | -299 |
Mao Zhenhua | 180 | 0 | 0 | 0 | 180 |
Chau Chi Wai, Wilton | 180 | 0 | 0 | 0 | 180 |
Wu Peng | 120 | 0 | 0 | 0 | 120 |
Gao Guanjiang (former INED) | 51 | 0 | 0 | 0 | 51 |
Yang Yu (former INED) | 0 | 0 | 0 | 0 | 0 |
Total | 531 | 2,000 | 18 | -856 | 1,693 |
Major Shareholders
| Holder | Shares | Stake | Source / date |
|---|---|---|---|
Zhou Xuzhou (via Shunda Investment Ltd and related vehicles) | 2,310,076,761 | ≈56.4% | [MS], Apr 2024 |
Zhou Xuzhou (alternative aggregator figure) | — | ≈59.7% | [SWS] (different date/denominator; discrepancy noted) |
Zeng Wentao | — | ≈1.85% | [SWS] |
Zhou Wen Chuan | 31,938,000 | ≈0.78% | [MS], Mar 2024 |
Total insiders | — | ≈66.3% | [SA] |
Institutions | — | ≈2.8% | [SA] |
Free float | ≈1.37bn shares | ≈34% | [SA] |
Board & Management Changes
| Date | Change |
|---|---|
| 2023 | INEDs Gao Guanjiang and later Dr. Yang Yu departed; Mr. Chen Shi joined (by Apr 2024) [DIR23], [DIR24], [WEBB] |
31 Dec 2025 | Change of company secretary; change in nomination committee composition [MS] |
21 Apr 2026 | 2026 Share Award Scheme adopted (10% scheme limit, 1% service-provider sublimit; 99.98% approval) [SGM26] |
3 Jul 2026 | 5,328,000 awarded shares granted from treasury [IR26] |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Relative positioning (qualitative unless stated) |
|---|---|---|
Recombinant collagen / efficacy skincare | Giant Biogene (2367.HK) | — |
Hyaluronic acid / functional skincare | Bloomage Biotech (688363.SH) | — |
Injectable aesthetics | Imeik Technology (300896.SZ) | — |
Medical aesthetics clinics (HK/PRC) | Perfect Medical Health Management (1830.HK) | — |
Medical aesthetics clinics | Miricor Enterprises (1827.HK) | — |
Medical aesthetics chains (private) | BeauCare Clinics (聯合麗格) — also a channel partner | Large private chain; not publicly disclosed |
Aesthetics platform | So-Young International (NASDAQ: SY) | — |
Cell therapy (investee competitors) | Shanghai Cellular Biopharmaceutical, Hrain Biotech, other NMPA MSC IND sponsors | Wingor Bio is a small private player |
CBD wellness (Europe) | Charlotte's Web (TSX: CWEB), numerous private EU brands | AlpReleaf is niche (Europe revenue HK$1.2m in FY2025) |
PRC commercial leasing | Local landlords and developers in Jiangsu/Anhui | Meilleure is a price-taker with ≈HK$19m rent |
Melbourne townhouse development | Local Australian developers | Single project |
Peer Comparison FY2025
| Metric | Meilleure Health FY2025 | Giant Biogene FY2024 | Bloomage FY2024 | Imeik FY2024 |
|---|---|---|---|---|
Revenue | HK$36.5m | ≈RMB5.5bn | ≈RMB5.4bn | ≈RMB3.0bn |
Revenue growth | −27.9% | Strong double-digit growth | Decline | Decline |
Gross margin | 62.0% | ≈80%+ | ≈70%+ | ≈90%+ |
R&D intensity | — | Disclosed (mid-single-digit %) | Disclosed (high-single-digit %) | Disclosed (≈10%+) |
“—” = not publicly disclosed.
Recent Developments
Headcount moved from 46 (end-2024) to 42 (end-2025) to 43 (mid-2026).



